IL266011B2 - Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules - Google Patents

Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules

Info

Publication number
IL266011B2
IL266011B2 IL266011A IL26601119A IL266011B2 IL 266011 B2 IL266011 B2 IL 266011B2 IL 266011 A IL266011 A IL 266011A IL 26601119 A IL26601119 A IL 26601119A IL 266011 B2 IL266011 B2 IL 266011B2
Authority
IL
Israel
Prior art keywords
vector
cmv
mhc
mir
cell
Prior art date
Application number
IL266011A
Other languages
English (en)
Hebrew (he)
Other versions
IL266011B1 (en
IL266011A (en
Original Assignee
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science filed Critical Univ Oregon Health & Science
Publication of IL266011A publication Critical patent/IL266011A/en
Publication of IL266011B1 publication Critical patent/IL266011B1/en
Publication of IL266011B2 publication Critical patent/IL266011B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL266011A 2016-10-18 2017-10-18 Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules IL266011B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662409840P 2016-10-18 2016-10-18
PCT/US2017/057106 WO2018075591A1 (en) 2016-10-18 2017-10-18 Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules

Publications (3)

Publication Number Publication Date
IL266011A IL266011A (en) 2019-06-30
IL266011B1 IL266011B1 (en) 2023-11-01
IL266011B2 true IL266011B2 (en) 2024-03-01

Family

ID=62018862

Family Applications (1)

Application Number Title Priority Date Filing Date
IL266011A IL266011B2 (en) 2016-10-18 2017-10-18 Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules

Country Status (22)

Country Link
US (2) US10532099B2 (enExample)
EP (1) EP3529363B1 (enExample)
JP (2) JP2019531745A (enExample)
KR (1) KR102604486B1 (enExample)
CN (1) CN110036112B (enExample)
AU (1) AU2017346788A1 (enExample)
BR (1) BR112019007982A2 (enExample)
CA (1) CA3040303A1 (enExample)
CL (1) CL2019001054A1 (enExample)
CO (1) CO2019004102A2 (enExample)
CR (1) CR20190205A (enExample)
DO (1) DOP2019000086A (enExample)
EA (1) EA201990937A1 (enExample)
EC (1) ECSP19031754A (enExample)
IL (1) IL266011B2 (enExample)
MA (1) MA46588A (enExample)
MX (1) MX2019004518A (enExample)
PE (1) PE20190840A1 (enExample)
SG (1) SG11201903340TA (enExample)
TN (1) TN2019000124A1 (enExample)
UA (1) UA126860C2 (enExample)
WO (1) WO2018075591A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3333265T1 (sl) 2010-05-14 2020-08-31 Oregon Health & Science University Rekombinantni HCMV in RHCMV vektorji, ki kodirajo heterologni antigen izoliran iz virusa hepatitisa B virus in njihove uporabe
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
HRP20181930T1 (hr) 2013-03-05 2019-01-11 Oregon Health & Science University Citomegalovirus vektori za kontroliranje ciljanja t-stanica
CN107002048B (zh) 2014-07-16 2021-07-06 俄勒冈健康与科学大学 包含外源抗原的人巨细胞病毒
CA2976245A1 (en) 2015-02-10 2016-08-18 Oregon Health & Science University Methods and compositions useful in generating non canonical cd8+ t cell responses
US10688164B2 (en) 2015-11-20 2020-06-23 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
MX2019004518A (es) 2016-10-18 2019-06-17 Univ Oregon Health & Science Vectores de citomegalovirus que provocan celulas t restringidas por moleculas del complejo mayor de histocompatibilidad e.
US11077185B2 (en) 2019-03-21 2021-08-03 21C Bio Vaccine to pathogenic immune activation cells during infections
US10632186B1 (en) 2019-03-21 2020-04-28 21C Bio Vaccine to pathogenic immune activation cells during infections
CN114025792A (zh) * 2019-03-21 2022-02-08 21C生物公司 针对感染期间的致病性免疫激活细胞的疫苗
CN113950334B (zh) * 2019-06-07 2025-01-28 俄勒冈健康与科学大学 乙型肝炎病毒特异性t细胞应答
US20220257740A1 (en) * 2019-06-07 2022-08-18 Oregon Health & Science University Tumor-associated antigen-specific t cell responses
MY210519A (en) * 2019-08-20 2025-09-29 Univ Oregon Health & Science Modulation of t cell responses by ul18 of human cytomegalovirus
WO2021045969A1 (en) 2019-08-29 2021-03-11 Vir Biotechnology, Inc. Hepatitis b virus vaccines
EP4076510A4 (en) * 2019-12-16 2024-01-10 Oregon Health & Science University MULTI-SPECIFIC T CELL RECEPTORS
US20240384296A1 (en) 2021-08-31 2024-11-21 Vir Biotechnology, Inc. Recombinant hcmv vectors and uses thereof
IL310667A (en) 2021-08-31 2024-04-01 Vir Biotechnology Inc Tuberculosis vaccines
EP4630027A1 (en) 2022-12-09 2025-10-15 DYS-Immune Therapeutics Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011293A1 (en) * 2014-07-16 2016-01-21 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
ATE118822T1 (de) 1987-06-26 1995-03-15 Syntro Corp Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
EP1092775A1 (en) 1991-07-05 2001-04-18 American Cyanamid Company Methods for identifiying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegalovirus
AU7192394A (en) 1993-07-19 1995-02-20 Cantab Pharmaceuticals Research Limited Production method for preparation of disabled viruses
DE69535125T2 (de) 1994-04-29 2007-08-30 Pharmacia & Upjohn Co. Llc, Kalamazoo Impfstoff gegen felines immunodefizienz-virus
US5846806A (en) 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
CA2211743A1 (en) 1995-02-21 1996-08-29 Cantab Pharmaceuticals Research Limited Viral preparations, vectors, immunogens, and vaccines
JPH11503024A (ja) 1995-04-04 1999-03-23 セル・ジェネシス・インコーポレイテッド 細胞表面のクラスｉ ｍｈｃタンパク質の低レベルを有する遺伝子学的に修飾された細胞の移植
ATE288764T1 (de) 1996-07-31 2005-02-15 Ortho Mcneil Pharm Inc Erkennung von menschlichen cytomegalovirus genes, welche die expression von mhc klasse i schweren ketten erniedrigen
US20030138454A1 (en) 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
DE19733364A1 (de) 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms
AU3910097A (en) 1997-08-05 1999-03-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Live recombinant vaccine comprising inefficiently or non-replicating vir us
US7204990B1 (en) 2000-11-28 2007-04-17 Medimmune Vaccines, Inc. Attenuation of cytomegalovirus virulence
CA2437201C (en) 2001-02-02 2008-11-18 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
WO2002066629A2 (en) 2001-02-21 2002-08-29 Gabriele Hahn Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
GB0122232D0 (en) 2001-09-14 2001-11-07 Medical Res Council Gene expression
AU2002362368B2 (en) 2001-09-20 2006-09-21 Glaxo Group Limited HIV-gag codon-optimised DNA vaccines
US20030118568A1 (en) 2001-12-18 2003-06-26 Board Of Trustees Of The University Of Arkansas Viral stealth technology to prevent T cell-mediated rejection of xenografts
US20060073123A1 (en) 2002-04-30 2006-04-06 Jie Mi Adenovirus vectors for immunotherapy
DE10232322A1 (de) 2002-07-16 2004-07-29 Hahn, Gabriele, Dr. Viral kodierte CxC determinieren den Gewebetropismus von HCMV
US7407744B2 (en) 2003-07-25 2008-08-05 The Regents Of The University Of California Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors
US20080199493A1 (en) 2004-05-25 2008-08-21 Picker Louis J Siv and Hiv Vaccination Using Rhcmv- and Hcmv-Based Vaccine Vectors
EP1602676A1 (en) 2004-06-01 2005-12-07 SOLVAY (Société Anonyme) Catalytic compositions
US20080044384A1 (en) 2004-06-25 2008-02-21 Medlmmune Vaccines, Inc. Recombinant Human Cytomegalovirus And Vaccines Comprising Heterologous Antigens
EP1888622A1 (en) 2005-05-23 2008-02-20 Oxxon Therapeutics Ltd. Compositions for inducing an immune response against hepatitis b
US8765146B2 (en) 2005-08-31 2014-07-01 Genvec, Inc. Adenoviral vector-based malaria vaccines
WO2008112146A2 (en) 2007-03-07 2008-09-18 The Trustees Of The University Of Pennsylvania 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction
JP2010532764A (ja) 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
CA2703279C (en) 2007-10-30 2014-04-22 Genentech, Inc. Antibody purification by cation exchange chromatography
JP2012519484A (ja) 2009-03-06 2012-08-30 マウント・シナイ・スクール・オヴ・メディシン マイクロｒｎａ応答要素を含む弱毒化生インフルエンザウイルスワクチン
ES2786039T3 (es) 2009-04-30 2020-10-08 Ospedale San Raffaele Srl Vector génico
KR20120105543A (ko) 2009-12-23 2012-09-25 4-안티바디 아게 인간 사이토메갈로바이러스에 대한 결합 멤버
EP2529227B1 (en) 2010-01-27 2015-10-07 Oregon Health & Science University Cytomegalovirus-based immunogenic preparations
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
ES2679245T3 (es) 2010-05-05 2018-08-23 Sirion Biotech Gmbh Vacuna contra la infección por beta-herpesvirus y uso de la misma
SI3333265T1 (sl) * 2010-05-14 2020-08-31 Oregon Health & Science University Rekombinantni HCMV in RHCMV vektorji, ki kodirajo heterologni antigen izoliran iz virusa hepatitisa B virus in njihove uporabe
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
US20140227708A1 (en) 2011-09-16 2014-08-14 Oregon Health & Science University Methods and kits used in identifying microrna targets
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
US20150307850A1 (en) 2012-12-04 2015-10-29 Merck Sharp & Dohme Corp. Conditional replicating viral vectors
HRP20181930T1 (hr) 2013-03-05 2019-01-11 Oregon Health & Science University Citomegalovirus vektori za kontroliranje ciljanja t-stanica
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
CA2976245A1 (en) 2015-02-10 2016-08-18 Oregon Health & Science University Methods and compositions useful in generating non canonical cd8+ t cell responses
US10688164B2 (en) 2015-11-20 2020-06-23 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
EP3474889A4 (en) * 2016-06-22 2020-04-29 International AIDS Vaccine Initiative, Inc. RECOMBINANT CYTOMEGALOVIRUS VECTORS FOR USE AS TUBERCULOSIS VACCINES
JP6987134B2 (ja) 2016-06-27 2021-12-22 ジュノー セラピューティクス インコーポレイテッド ペプチドエピトープを同定する方法、そのようなエピトープに結合する分子および関連用途
MX2019004518A (es) 2016-10-18 2019-06-17 Univ Oregon Health & Science Vectores de citomegalovirus que provocan celulas t restringidas por moleculas del complejo mayor de histocompatibilidad e.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011293A1 (en) * 2014-07-16 2016-01-21 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens

Also Published As

Publication number Publication date
CN110036112A (zh) 2019-07-19
EP3529363B1 (en) 2025-07-30
ECSP19031754A (es) 2019-05-31
CA3040303A1 (en) 2018-04-26
CO2019004102A2 (es) 2019-07-10
US20200237915A1 (en) 2020-07-30
KR20190064624A (ko) 2019-06-10
AU2017346788A8 (en) 2019-05-16
UA126860C2 (uk) 2023-02-15
SG11201903340TA (en) 2019-05-30
US10532099B2 (en) 2020-01-14
BR112019007982A2 (pt) 2019-07-02
EP3529363A4 (en) 2020-05-06
DOP2019000086A (es) 2019-07-31
PE20190840A1 (es) 2019-06-17
WO2018075591A8 (en) 2019-04-04
CN110036112B (zh) 2024-05-10
MA46588A (fr) 2021-04-14
AU2017346788A1 (en) 2019-05-02
JP2019531745A (ja) 2019-11-07
EP3529363A1 (en) 2019-08-28
IL266011B1 (en) 2023-11-01
JP2023002716A (ja) 2023-01-10
CL2019001054A1 (es) 2019-09-27
US20180133321A1 (en) 2018-05-17
US11305015B2 (en) 2022-04-19
EA201990937A1 (ru) 2019-09-30
CR20190205A (es) 2020-01-07
IL266011A (en) 2019-06-30
KR102604486B1 (ko) 2023-11-22
MX2019004518A (es) 2019-06-17
TN2019000124A1 (en) 2020-10-05
JP7478794B2 (ja) 2024-05-07
WO2018075591A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
US11305015B2 (en) Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
US20200368333A1 (en) Cmv vectors comprising microrna recognition elements
US20200392534A1 (en) Methods and Compositions Useful In Generating Non Canonical CD8+ T Cell Responses
JP2025131719A (ja) ヒトサイトメガロウイルスのｕｌ１８によるｔ細胞応答の調節
OA19584A (en) Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
EA042630B1 (ru) Цитомегаловирусные векторы, выбирающие t-клетки, ограниченные по молекулам главного комплекса гистосовместимости e
HK40011160A (en) Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
OA20580A (en) Modulation of T cell responses by UL18 of human cytomegalovirus.
HK40073534A (en) Modulation of t cell responses by ul18 of human cytomegalovirus
HK1260171A1 (en) Cmv vectors comprising microrna recognition elements
EA046730B1 (ru) Модуляция т-клеточных ответов посредством ul18 цитомегаловируса человека